Tumor aggression-defense index–a novel indicator to predicts recurrence and survival in stage II-III colorectal cancer by Tong Wu, Lin Fang, Yuli Ruan, Mengde Shi, Dan Su, Yue Ma, Ming Ma, Bojun Wang, Yuanyu Liao, Shuling Han, Xiaolin Lu, Chunhui Zhang, Chao Liu, Yanqiao Zhang

Get full text

Efficacy and safety of surufatinib plus toripalimab in treatment-naive, PD-L1-positive, advanced or metastatic non-small-cell lung cancer and previously treated small-cell lung can... by Ying Cheng, Panpan Zhang, Ming Lu, Zhendong Chen, Lijie Song, Si Shi, Feng Ye, Xing Zhang, Baorui Liu, Dongmei Ji, Yanqiao Zhang, Weiguo Su, Michael Shi, Songhua Fan, Panfeng Tan, Chen Zhong

Get full text

The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial by Da Xu, Hongwei Wang, Quan Bao, Kemin Jin, Ming Liu, Wei Liu, Xiaoluan Yan, Lijun Wang, Yanqiao Zhang, Guangyu Wang, Yue Ma, Zhigang Ma, Chunhui Zhang, Jiebing Tang, Sha Wang, Jiaohui Pang, Ting Xu, Kun Wang, Baocai Xing

Get full text

Retrospective analysis of disease characteristics and treatment patterns among patients with esophageal cancer across 14 surgically represented centers by Zhihao Lu, Mingfei Geng, Yongtao Han, Jianzhong Cao, Jun Wang, Tianshu Liu, Xianglin Yuan, Xue Meng, Yanqiao Zhang, Rong Zhao, Lixin Wan, Enxiao Li, Wenran Wang, Zhijie Li, Danfeng Shi, Jing Qian, Si Shi, Fengshi Dong, Lin Shen

Get full text